Literature DB >> 22441524

[Long-term outcome with end-stage renal disease - survival is not enough: does dialysis or kidney transplantation matter?].

K-H Schulz1, F Thaiss.   

Abstract

Patients with end-stage renal disease require renal replacement therapy with either dialysis or kidney transplantation. Survival and quality of life (QoL) after transplantation are superior to chronic dialysis. Early living donor kidney transplantation is best for patient and graft survival. Preemptive living-related kidney transplantation therefore is the best medical treatment option for these patients. Patients with end-stage renal disease suffer from multiple physical and psychological complaints. The prevalence of depressive disorders is 20-25% in this population. Studies on QoL in children after kidney transplantation show a reduced physical QoL, but an overall good psychological QoL. Alarming results of numerous studies are the high non-adherence rates in adolescents. Especially exercise interventions during dialysis and after kidney transplantation show promising results. Whether QoL of patients will improve with new approaches to immunosuppressive therapy remains to be evaluated in future studies.

Entities:  

Mesh:

Year:  2012        PMID: 22441524     DOI: 10.1007/s00103-012-1450-2

Source DB:  PubMed          Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz        ISSN: 1436-9990            Impact factor:   1.513


  2 in total

1.  Comparison of Open and Robot-Assisted Kidney Transplantation in terms of Perioperative and Postoperative Outcomes.

Authors:  Serdar Karadag; Mithat Eksi; Osman Ozdemir; Taner Kargi; Ahmet Haciislamoglu; Ismail Evren; Hakan Polat; Dogukan Sokmen; Deniz Noyan Ozlu; Selcuk Sahin; Volkan Tugcu
Journal:  Int J Clin Pract       Date:  2022-05-06       Impact factor: 3.149

2.  Psychological stress and strain on employees in dialysis facilities: a cross-sectional study with the Copenhagen Psychosocial Questionnaire.

Authors:  Maren Kersten; Agnessa Kozak; Dana Wendeler; Lara Paderow; Matthias Nübling; Albert Nienhaus
Journal:  J Occup Med Toxicol       Date:  2014-02-05       Impact factor: 2.646

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.